Treatment with PRIMA-1Met significantly reduces tumor volume and decreases the p53 protein and the cystine-glutamate antiporter system, which regulates the homeostasis of excitatory neurotransmitters in the brain. (NCT03072043; NCT02999893; NCT0358807). The gene discussed is TP53; the disease is neoplasm.